Atlas Trials

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Clinical trial NCT06504940 · RECRUITING

Trial details

NCT number
NCT06504940
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone Lymphoma
Start date
2024-06-28
Primary completion
2027-07-08
Enrollment
69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.